Table 1

Baseline demographics and clinical characteristics in patients who did or did not achieve sustained LDA according to DAPSA LDA or MDA response

Baseline characteristicsDAPSA LDA+REMMDA
Variables, n (%) unless otherwise specifiedWith sustained response
(N=396)
Without sustained response
(N=112)
With sustained response
(N=278)
Without sustained response
(N=266)
Age, mean (SD), years46.9 (12.4)53.0 (11.2)45.5 (12.1)51.2 (11.7)
Male225 (56.8)48 (42.9)166 (59.7)123 (46.2)
BMI, mean (SD), kg/m228.2 (5.6)31.0 (7.1)*27.7 (4.9)29.9 (6.9)
Smoking—yes73 (18.4)18 (16.1)55 (19.8)44 (16.5)
Time since first diagnosis of PsA, mean (SD), years6.3 (6.9)8.0 (8.0)5.8 (6.8)7.3 (7.4)
Biologic-naïve patients318 (80.3)61 (54.5)229 (82.4)178 (66.9)
Methotrexate use at randomisation216 (54.5)60 (53.6)146 (52.5)144 (54.1)
Systemic glucocorticoid use at randomisation53 (13.4)25 (22.3)38 (13.7)49 (18.4)
CRP ≥10 mg/dL96 (24.2)36 (32.1)69 (24.8)71 (26.7)
Patients with specific disease characteristics
 TJC (78 joints), mean (SD)17.8 (13.2)29.2 (18.8)16.1 (12.4)25.4 (17.3)
 SJC (76 joints), mean (SD)10.7 (8.7)14.1 (12.4)10.2 (7.7)12.5 (11.2)
 HAQ-DI score, mean (SD)1.1 (0.6)1.6 (0.6)1.0 (0.6)1.5 (0.6)
 PsA pain (VAS 0–100 mm), mean (SD)52.5 (24.1)61.9 (22.5)50.3 (25.0)59.1 (21.6)
 Patients’ global assessment (VAS 0–100 mm), mean (SD)53.3 (22.9)57.8 (24.4)51.7 (23.6)57.5 (22.4)
 Physician’s global assessment (VAS 0–100 mm), mean (SD)55.9 (19.1)59.3 (18.7)54.4 (19.4)58.7 (18.1)
 Presence of enthesitis221 (55.8)87 (77.7)147 (52.9)184 (69.2)
 Presence of dactylitis155 (39.1)50 (44.6)116 (41.7)97 (36.5)
 Psoriasis affecting ≥3% of BSA223 (56.3)51 (45.5)159 (57.2)137 (51.5)
 Psoriasis of nail259 (65.4)70 (62.5)185 (66.5)171 (64.3)
  • *Data for one patient was missing. Patients having DAPSA assessment at weeks 24 and 104: SEC 150 mg LD, N=167; SEC 150 mg NL, N=162; SEC 300 mg, N=179. Patients having MDA assessment at weeks 24 and 104: SEC 150 mg LD, N=184; SEC 150 mg NL, N=169; SEC 300 mg, N=191.

  • BMI, body mass index; BSA, body surface area; CRP, C reactive protein; DAPSA, Disease Activity index in Psoriatic Arthritis; HAQ-DI, Health Assessment Questionnaire Disability Index; LD, loading dose; LDA, low disease activity; MDA, minimal disease activity; n, number of evaluable patients; N, number of patients with DAPSA and MDA assessments at weeks 24 and 104 ; NL, without loading dose; PsA, psoriatic arthritis; SEC, secukinumab; SJC, swollen joint count; TJC, tender joint count; VAS, Visual Analogue Scale.